SCHEMBL4933913

SCHEMBL4933913

COc1ccc(-c2ccnc3[nH]c(-c4cccc(C(=O)O)c4)nc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C19 P33261 1/20 0.47
GFER P55789 1/20 0.47
CHEK2 O96017 1/20 0.46
TBK1 Q9UHD2 1/20 0.46
PIN1 Q13526 1/20 0.44
PTPN11 Q06124 2/20 0.44
MAP4K4 O95819 1/20 0.43
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4940389 0.92 NEK1 (0.45) KDM4EALDH1A1MAPTPARP1PLA2G2A
SCHEMBL4930977 0.88 TBK1 (0.57) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL4937764 0.87 TBK1 (0.47) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL14027966 0.86 ALDH1A1 (0.46) SMN1; SMN2MEN1KMT2AKDM4EALDH1A1
SCHEMBL4934472 0.85 PRKCI (0.48) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL4941171 0.85 ALDH1A1 (0.45) SMN1; SMN2MEN1KMT2AKDM4EALDH1A1
SCHEMBL4941364 0.84 MAPK14 (0.52) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL14027967 0.84 GSK3A (0.50) RAB9AMEN1KMT2AKDM4EALDH1A1
SCHEMBL5014824 0.84 ALDH1A1 (0.57) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL14027954 0.84 FYN (0.49) RAB9ASMN1; SMN2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255085-A1 Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US claimed
US-20080255085-A1 Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed
US-20080255085-A1 Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed
US-20080255085-A1 Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed
WO-2007040438-A2 NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255085-A1 Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders GSK3B, GSK3A, PYGB RAB9A 2521/4885SMN1; SMN2 328/4885MEN1 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.